These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10992368)

  • 1. Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases.
    Wasson JH; Bubolz TA; Lu-Yao GL; Walker-Corkery E; Hammond CS; Barry MJ
    J Urol; 2000 Oct; 164(4):1212-5. PubMed ID: 10992368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT).
    Lu-Yao GL; Barry MJ; Chang CH; Wasson JH; Wennberg JE
    Urology; 1994 Nov; 44(5):692-8; discussion 698-9. PubMed ID: 7526526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unequal use of new technologies by race: the use of new prostate surgeries (transurethral needle ablation, transurethral microwave therapy and laser) among elderly Medicare beneficiaries.
    Yu X; McBean AM; Caldwell DS
    J Urol; 2006 May; 175(5):1830-5; discussion 1835. PubMed ID: 16600772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies.
    Yu X; Elliott SP; Wilt TJ; McBean AM
    J Urol; 2008 Jul; 180(1):241-5; discussion 245. PubMed ID: 18499180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Race Associated with the Surgical Treatment for Benign Prostatic Hyperplasia? An Analysis of 30,000 Medicare Lives.
    Narang GL; Rojanasarot S; Cutone B; Humphreys MR
    J Racial Ethn Health Disparities; 2024 Feb; 11(1):528-534. PubMed ID: 37095287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Claims Based Assessment of Reoperation and Acute Urinary Retention after Ambulatory Transurethral Surgery for Benign Prostatic Hyperplasia.
    Frendl DM; Chen YW; Chang DC; Kim MM
    J Urol; 2021 Feb; 205(2):532-538. PubMed ID: 33026901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia.
    Jeldres C; Isbarn H; Capitanio U; Zini L; Bhojani N; Shariat SF; Cloutier V; Lattouf JB; Duclos A; Jolivet-Tremblay M; Valiquette L; Saad F; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
    J Urol; 2009 Aug; 182(2):626-32. PubMed ID: 19535100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population based trends in the surgical treatment of benign prostatic hyperplasia.
    Schroeck FR; Hollingsworth JM; Kaufman SR; Hollenbeck BK; Wei JT
    J Urol; 2012 Nov; 188(5):1837-41. PubMed ID: 22999698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia.
    Bruskewitz R; Issa MM; Roehrborn CG; Naslund MJ; Perez-Marrero R; Shumaker BP; Oesterling JE
    J Urol; 1998 May; 159(5):1588-93; discussion 1593-4. PubMed ID: 9554360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
    Rosario DJ; Phillips JT; Chapple CR
    J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).
    Elshal AM; Elmansy HM; Elhilali MM
    BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients.
    Reich O; Gratzke C; Bachmann A; Seitz M; Schlenker B; Hermanek P; Lack N; Stief CG;
    J Urol; 2008 Jul; 180(1):246-9. PubMed ID: 18499179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bipolar transurethral enucleation and resection of the prostate versus bipolar resection of the prostate for prostates larger than 60gr: A retrospective study at a single academic tertiary care center.
    Wei Y; Xu N; Chen SH; Li XD; Zheng QS; Lin YZ; Xue XY
    Int Braz J Urol; 2016; 42(4):747-56. PubMed ID: 27564286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of transurethral resection of the prostate and combined transurethral resection and vaporization of the prostate as a therapeutic alternative in men with benign prostatic hyperplasia.
    Küpeli S; Yilmaz E; Soygür T; Budak M
    J Endourol; 2001 Apr; 15(3):317-21. PubMed ID: 11339401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Holmium:YAG transurethral incision versus laser photoselective vaporization for benign prostatic hyperplasia in a small prostate.
    Elshal AM; Elkoushy MA; Elmansy HM; Sampalis J; Elhilali MM
    J Urol; 2014 Jan; 191(1):148-54. PubMed ID: 23845460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors of recurrence after transurethral resection of the prostate due to benign prostate hyperplasia].
    Lai JY; Song LM; Zhu YC; Wei Q
    Zhonghua Wai Ke Za Zhi; 2010 Jan; 48(2):103-7. PubMed ID: 20302727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008).
    Malaeb BS; Yu X; McBean AM; Elliott SP
    Urology; 2012 May; 79(5):1111-6. PubMed ID: 22546389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams).
    Tan AH; Gilling PJ; Kennett KM; Frampton C; Westenberg AM; Fraundorfer MR
    J Urol; 2003 Oct; 170(4 Pt 1):1270-4. PubMed ID: 14501739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
    Ornstein DK; Rao GS; Smith DS; Andriole GL
    J Urol; 1997 Mar; 157(3):880-3; discussion 883-4. PubMed ID: 9072591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis at 2 years of surgical treatment of benign prostatic hyperplasia by photoselective vaporization of the prostate with GreenLight-Photo vaporization 120 W versus transurethral resection of the prostate.
    Benejam-Gual JM; Sanz-Granda A; García-Miralles Grávalos R; Severa-Ruíz de Velasco A; Pons-Viver J
    Actas Urol Esp; 2014 May; 38(4):238-43. PubMed ID: 24300307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.